288 related articles for article (PubMed ID: 6441963)
41. [Appearance of circulating immune complexes in patients with Hodgkin's disease and the etiology of this disease].
Dziewulska-Bokiniec A; Sztaba-Kania M
Wiad Lek; 1992 Oct; 45(19-20):740-3. PubMed ID: 1296377
[TBL] [Abstract][Full Text] [Related]
42. Hepatitis C virus infection and lymphoproliferative diseases: prospective study on 1,576 patients in France.
Hausfater P; Cacoub P; Sterkers Y; Thibault V; Amoura Z; Nguyen L; Ghillani P; Leblond V; Piette JC
Am J Hematol; 2001 Jul; 67(3):168-71. PubMed ID: 11391713
[TBL] [Abstract][Full Text] [Related]
43. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N
Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377
[TBL] [Abstract][Full Text] [Related]
44. Immune deficiency states associated with malignant disease in man.
Harris J; Bagai RC
Med Clin North Am; 1972 Mar; 56(2):501-14. PubMed ID: 4623010
[No Abstract] [Full Text] [Related]
45. [Quantification of granulocyte protection in hemoblastoses].
Senn HJ; Jungi WF
Folia Haematol Int Mag Klin Morphol Blutforsch; 1974; 101(3):337-46. PubMed ID: 4139053
[No Abstract] [Full Text] [Related]
46. Simultaneous study of platelets and phagocytes in myeloproliferative disorders.
Laharrague PF; Corberand JX; Fillola G; Boneu BP; Pris JF
Biomed Pharmacother; 1984; 38(9-10):462-5. PubMed ID: 6597727
[TBL] [Abstract][Full Text] [Related]
47. [Circulating immune complexes in human leukemias].
Carpentier NA; Zubler RH; Lange GT; Lambert PH; Miescher PA
Schweiz Med Wochenschr; 1976 Oct; 106(40):1363-4. PubMed ID: 1070156
[TBL] [Abstract][Full Text] [Related]
48. Circulating immune complexes in uveitis.
Hańczyc P; Prastowska E; Wieczorek E
Arch Immunol Ther Exp (Warsz); 1987; 35(1):29-32. PubMed ID: 3632260
[TBL] [Abstract][Full Text] [Related]
49. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts.
Langebrake C; Creutzig U; Reinhardt D
Klin Padiatr; 2005; 217(3):126-34. PubMed ID: 15858703
[TBL] [Abstract][Full Text] [Related]
50. [An autopsy case of primary myelofibrosis with high value of circulating immune complexes, IgG(kappa) monoclonal gammopathy and extramedullary hematopoietic subcutaneous tumors].
Soga N; Sakai C; Shibata A; Honma K; Nemoto K
Rinsho Ketsueki; 1982 Nov; 23(11):1713-8. PubMed ID: 6820087
[No Abstract] [Full Text] [Related]
51. Immunologic dysfunction in the myeloproliferative disorders.
DiBella NJ; Brown GL
Cancer; 1978 Jul; 42(1):149-58. PubMed ID: 276412
[TBL] [Abstract][Full Text] [Related]
52. [Pathogenesis of immunologic deficiency diseases associated with lymphoproliferative disorders].
Ponzone A; Tarocco RP; Nicola P
Minerva Pediatr; 1970 Dec; 22(51):2542-60. PubMed ID: 4993895
[No Abstract] [Full Text] [Related]
53. [Circulating immune complexes in multiple sclerosis].
Hrazdira CL; Hrazdirová V; Polcáková M
Cesk Neurol Neurochir; 1984 May; 47(3):173-6. PubMed ID: 6467415
[No Abstract] [Full Text] [Related]
54. Circulating immune complexes in diabetics: the influence of sex, age, duration of disease and type of treatment.
Di Mario U; Irvine WJ; Guy K; Borsey DQ; Iavicoli M; Ventriglia L
J Clin Lab Immunol; 1983 May; 11(1):17-20. PubMed ID: 6348294
[TBL] [Abstract][Full Text] [Related]
55. [Chromosome findings in myeloproliferative diseases].
Hellriegel KP
Internist (Berl); 1968 Dec; 9(12):465-70. PubMed ID: 4891471
[No Abstract] [Full Text] [Related]
56. [Chronic myeloproliferative syndromes].
de Ozalla CB; García Suárez J
Rev Clin Esp; 1999 Apr; 199 Suppl 1():28-36. PubMed ID: 10422448
[No Abstract] [Full Text] [Related]
57. Clinical significance of circulating immune complexes. Effect of plasmapheresis.
Hollán SR
Haematologia (Budap); 1978-1979; 12(1-4):69-83. PubMed ID: 395044
[No Abstract] [Full Text] [Related]
58. [Immunological classification of lymphoproliferative conditions].
Froland SS
Tidsskr Nor Laegeforen; 1974 Nov; 94(32):2220-3. PubMed ID: 4531116
[No Abstract] [Full Text] [Related]
59. Platelet aggregation and platelet factor 3 activity in myeloproliferative disorders.
Tangün Y
Thromb Diath Haemorrh; 1971 Jun; 25(2):241-51. PubMed ID: 5284903
[No Abstract] [Full Text] [Related]
60. [Cytostatic activity of granulocytes in patients with acute leukemia].
Vartanian NL; Luganova IS; Blinov MN
Eksp Onkol; 1988; 10(1):49-52. PubMed ID: 3163545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
